Angiotensin II receptor antagonists: from science to clinical practice Takeda Satellite Symposium

Angiotensin II Receptor Antagonists: From Science to Clinical Practice Takeda Satellite Symposium Opening Remarks – Professor Kikuo Arakawa

Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists

• PS Sever

Angiotensin II receptor pharmacology and AT₁-receptor blockers

• O Chung
• T Csikós
• T Unger

Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury

• M Miyazaki
• T Wada
• S Takai

Clinical efficacy and tolerability of candesartan cilexetil

• T Ogihara
• K Arakawa
• on behalf of the Candesartan Study Groups in Japan

Discussion 1 New refinements in the approach to hypertension management

Cardiac and vascular remodelling: effect of antihypertensive agents

• J-M Mallion
• J-P Baguet
• R De Gaudemaris

Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress

• T Yamazaki
• Y Yazaki

Discussion 2 (Part A)

ACE-I vs angiotensin II receptor antagonists: prevention of renal injury in chronic rat models

• MW Taal
• BM Brenner

Effects of candesartan on the proteinuria of chronic glomerulonephritis

• Kiyoshi Kurokawa

Discussion 2 (Part B)

Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats

• K Sugimoto
• S Tsuruoka
• A Fujimura

Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension

• K Higashiura
• N Ura
• K Shimamoto

Pharmacologic properties of candesartan cilexetil—possible mechanisms of long-acting antihypertensive action

• Y Inada
• M Ojima
• T Naka

Discussion 3

Closing Remarks–Professor Peter Sever